 |
|
Level of Axillary Involvement by Lymph Node Metastases From Breast Cancer Is Not an Independent Predictor of Survival
Richard J. Barth, Jr, MD;
David N. Danforth, Jr, MD;
David J. Venzon, PhD;
Karen L. Straus, MD;
Teresa d'Angelo, RN;
Maria J. Merino, MD;
Lynn Gerber, MD
Arch Surg. 1991;126(5):574-577.
Abstract
| |
• We examined the relationship of axillary level of lymph node metastases from clinical stage I and II breast cancer to overall survival and disease-free survival rates in 135 patients who underwent complete axillary lymph node dissection to determine if anatomic level of axillary involvement (I vs II vs III) is an independent prognostic factor. All patients underwent either modified radical mastectomy or lumpectomy with axillary dissection and whole breast radiotherapy for breast cancer. Median follow-up was 6.9 years. We found no difference in overall survival or disease-free survival between patients whose highest or only level of axillary involvement was level I compared with patients whose highest or only level was II. Although patients whose highest level of nodal involvement was III had significantly worse overall survival and disease-free survival rates than patients whose highest nodal involvement was I or II, when patients were stratified by the total number of positive nodes (one to three vs four or more), there was no difference in overall survival or disease-free survival rates between levels I, II, and III. These findings indicate that the level of axillary involvement for stage II breast cancer is not of independent prognostic significance.
(Arch Surg. 1991;126:574-577)
Author Affiliations
From the Surgery (Drs Barth and Danforth) and Radiation Oncology (Dr Straus and Ms d'Angelo) Branches, the Laboratory of Pathology (Dr Merino), and the Biostatistics and Data Management Section (Dr Venzon), National Cancer Institute, and the Department of Rehabilitation Medicine (Dr Gerber), Clinical Center, National Institutes of Health, Bethesda, Md. Read before the 43rd Annual Cancer Symposium of the Society of Surgical Oncology, Washington, DC, May 21, 1990.
Footnotes
Accepted for publication December 8, 1990.
Reprint requests to Bldg 10, Rm 2B38, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 (Dr Danforth).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
DNA Flow Cytometry Does Not Predict 5- or 10-Year Recurrence Rates for T1-2 Node-Negative Breast Cancer
Reed et al.
Arch Surg 2000;135:1422-1426.
ABSTRACT
| FULL TEXT
Treatment Differences and Other Prognostic Factors Related to Breast Cancer Survival: Delivery Systems and Medical Outcomes
Lee-Feldstein et al.
JAMA 1994;271:1163-1168.
ABSTRACT
|
